



State of play Commission Action Plan to Combat the rising threat from Antimicrobial Resistance: activities in the human sector

Joint Conference on Antimicrobial Resistance: State of play of the 5 year action plan, 11 December 2013

> DG Health and Consumers European Commission John-F. Ryan, Acting Director Public Health



### Action plan against the rising threats from antimicrobial resistance (COM (2011) 748) - 17 Nov 2011

5 year action planHolistic approach7 key areas12 concrete actions

DG SANCO

# Communication from the Commission to the European Parliament and the Council

Action plan against the rising threats from Antimicrobial Resistance

COM (2011) 748



### The 7 areas where action is needed

- **Appropriate use** of antimicrobials (humans and animals)
- **Prevention** microbial infections and their spread
- Development new effective antimicrobials or alternatives for treatment
- Improvement monitoring and surveillance (human and animal medicine)
- Cooperation with international partners to contain the risks of AMR
- Promotion **research** and innovation
- Improvement communication, education and training

Roadmap: http://ec.europa.eu/dgs/health\_consumer/docs/road-map-amr\_en.pdf 3





A EUROPEAN HEALTH INITIATIVE

# *Klebsiella pneumoniae:* percentage of carbapenem-resistant infections




### 2009

#### Source: EARS-Net, 2013

↑ and ↓ indicate a significant increasing or decreasing trend between 2009 and 2012. Trends were calculated with data from laboratories which consistently reported during this period.

### EU/EEA, 2009-12







## **Overview: Actions relating to the Human Sector**

- Action no 1: Strengthening the promotion of appropriate use of antimicrobials in human medicines in all Member States
- Action no 4: Strengthen infection prevention and control in healthcare settings
- Action no 6: Develop new effective antimicrobials or alternatives for treatment
- Action no 8: Develop and strengthen multilateral and bilateral commitments for the prevention and control of AMR in all sectors

5

- Action no 9: Strengthen surveillance systems on AMR and antimicrobial consumption in human medicine
- Action no 12: Communication, education and training survey and comparative effectiveness research



## Action 1: Appropriate use of antimicrobials in human medicines

1/2
 The EP and Commission decided to finance a Preparatory action to research and document the non-prudent use of antibiotics in human medicines across Europe (start beginning 2014)

### Objective:

-identify key factors driving the sales and non- prudent use of antibiotics in human medicines obtained without prescription

-assess level of enforcement of prescription only requirement -document best practices aimed at a more prudent use

-recommend policy options<sub>DG SANCO</sub>



# Action 1: Appropriate use of antimicrobials in human medicines 2/2

"Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem", EMA conference, 8-11-2013

- Appropriate use of antibiotics is the responsibility of all actors
- Prescription only antibiotics
- Up-to-date and evidence-based product information, reference to official guidance on the appropriate use

DG SANCO



# Action 4: Prevention and control of healthcare-associated infection

 First implementation report on the Council recommendation on patient safety including healthcare associated infections
 – adopted 13 November 2012

http://ec.europa.eu/health/patient\_safety/docs/council\_2009\_report\_en.pdf

- Second Commission implementation report under preparation (publication mid 2014)
- ECDC point prevalence survey of healthcare associatedinfections (HAI) and antimicrobial use in acute care hospitals published July 2013



# Action 6: Bringing new antibiotics to patients

"Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem", EMA conference, 8-11-2013

Authorisation of new antibacterials -clarity and flexibility of regulatary famework: "fit for purpose" -risk-benefit vs early access

Research and development

DG SANCO



# Action 8: International cooperation (human sector)

- WHO  $\rightarrow$  bilateral contacts and joint actions/meetings
- Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)
  Progress report (first quarter 2014)
- Bilateral collaboration with other countries:
  - -China → Human/veterinarian symposia March 2013
  - -DG-Sanco- Russian Federation subgroup on communicable diseases



### Action 9: Strengthen surveillance systems on AMR and antimicrobial consumption in human medicine

- Sustainability of the European Surveillance system of Antimicrobial Consumption (ESAC) ensured (transfer of ESAC to ECDC completed – ESAC-net)
- 1rst ESAC-net Report published
- 2<sup>nd</sup> ESAC-net Report (to be published early 2014)
- Addressing the lack of data on AMR and antimicrobial consumption in children: dedicated EU project (ARPEC) ongoing (about to be finalised)



# **Action 12: Communication**

European Antimicrobial Awareness Day (EAAD)

- Holistic approach: participation of Fédération Vétérinaires Européens (FVE) and Standing Committee of European Doctors (CPME)
- Nearly 1,000,000 impressions on Twitter
- Lightbulb video on Euronews  $\rightarrow$  9,405,000 people reached
- European Antimicrobial Awareness Day 2013 ECDC stakeholder event 15 November 2013
  - Overall theme: "Everyone's responsible"
  - Over 40 countries participating, growing into a global event



# **Action 12: Communication**

2nd Eurobarometer Survey on AMR (published 15 Nov 2013)

- designed to allow indication of trends in comparison to the 2009 last survey
- shows a modest positive evolution in EU citizens' use of and knowledge about antibiotics, since the last survey in 2009.
- 35% of respondents say they have taken antibiotics in the past year (a 5% decrease since the 2009 survey).
- 2% fewer people took antibiotics for the flu in 2013 compared with 2009: 18% vs. 20%.

*In 2013 more people are aware that antibiotics do not kill viruses than in 2009: 40% vs. 36%.* 



## **Discussion: Challenges**

- Improve the prudent use of antibiotics (including reduction of over the counter sales)
- > Infection prevention and healthcare settings
- Incentives for new antibiotics new business model



## Thank you



DG SANCO